Related Experiment Video
Updated: Jul 19, 2026
06:59
Trabecular Bone Microarchitecture Evaluation in an Osteoporosis Mouse Model
Published on: September 8, 2023
Fluoxetine treatment increases trabecular bone formation in mice
R Battaglino1, M Vokes, U Schulze-Späte
1Department of Cytokine Biology, Forsyth Institute, Boston, Massachusetts 02115, USA. rbattaglino@Forsyth.org
Journal of Cellular Biochemistry
|October 17, 2006
Summary
Fluoxetine, an antidepressant, increases bone mass in mice by affecting serotonin transporter activity. However, it does not prevent bone loss due to estrogen deficiency or inflammation.
Area of Science:
- Bone Biology
- Pharmacology
- Endocrinology
Background:
- A functional serotonin (5-HT) system is present in bone cells.
- The serotonin transporter (5-HTT) is crucial for osteoclast differentiation.
- Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine may impact bone metabolism.
Purpose of the Study:
- To investigate the in vivo effects of fluoxetine on bone metabolism.
- To determine if fluoxetine influences bone loss in models of estrogen deficiency and inflammation.
Main Methods:
- Systemic administration of fluoxetine to mice for 6 weeks.
- Micro-computed tomography (microCT) analysis of bone mass and structure.
- Evaluation of bone loss after ovariectomy and lipopolysaccharide (LPS) challenge.
Main Results:
- Fluoxetine treatment increased trabecular bone volume, number, and connectivity.
- Fluoxetine did not prevent bone loss in ovariectomized mice, indicating estrogen dependency.
- Fluoxetine mitigated bone loss and promoted bone gain during LPS-induced inflammation.
Conclusions:
- Fluoxetine enhances bone mass in vivo under normal and inflammatory conditions.
- The anabolic effects of fluoxetine on bone are dependent on estrogen.
- Antidepressants like fluoxetine may have significant implications for bone health.
